Rhythm Pharmaceuticals (NASDAQ:RYTM) has announced preliminary unaudited net revenues from global sales of IMCIVREE® for the Q4 and FY of 2024, pipeline advancement updates and upcoming milestones.
Some results have been hidden because they may be inaccessible to you